Mirae Asset Global ETFs Holdings’s Crinetics Pharmaceuticals CRNX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.67M	Buy	45,847 +3,845	+9%	+$172K	﹤0.01%	1260
2025 Q4	$1.96M	Sell	42,002 -7	-0%	-$312	﹤0.01%	1157
2025 Q3	$1.75M	Sell	42,009 -11,986	-22%	-$383K	﹤0.01%	1204
2025 Q2	$1.56M	Sell	53,995 -5,316	-9%	-$164K	﹤0.01%	1223
2025 Q1	$1.99M	Buy	59,311 +6,148	+12%	+$230K	﹤0.01%	1144
2024 Q4	$2.72M	Buy	53,163 +6,719	+14%	+$376K	0.01%	971
2024 Q3	$2.37M	Buy	46,444 +8,054	+21%	+$415K	0.01%	1046
2024 Q2	$1.71M	Buy	+38,390	New	+$1.77M	﹤0.01%	1152

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CRNX Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Crinetics Pharmaceuticals (CRNX) stake by 9.2% in Q1 2026, buying an estimated $172K and bringing the position to 45,847 shares worth $1.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1260.

Mirae Asset Global ETFs Holdings first reported a position in CRNX in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.72M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Mirae Asset Global ETFs Holdings held 45,847 shares of Crinetics Pharmaceuticals worth $1.67M as of Q1 2026.
Mirae Asset Global ETFs Holdings bought 3,845 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $172K.
Crinetics Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #1260 holding.
Mirae Asset Global ETFs Holdings first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Mirae Asset Global ETFs Holdings's Crinetics Pharmaceuticals position peaked at $2.72M in Q4 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.